Analyst firms · Raymond James · WVE
Raymond James WVE price target and rating history
Wave Life Sciences Inc. (WVE) · Health Care
Raymond James rates Wave Life Sciences Inc. (WVE) Outperform with a $14 price target, as of its latest action on Jun 11, 2025. It has published 3 rating actions on WVE since July 2023, including 1 upgrade and 0 downgrades. Across 6 firms with a WVE price target in the last 12 months, the median target is $21.
- Current rating
- Outperform
- Price target
- $14
- Median target, all firms
- $21
- Actions on WVE
- 3
Raymond James price target on WVE
Every Raymond James rating on WVE
- Jun 11, 2025
- Oct 16, 2024
- Jul 5, 2023
How other firms rate WVE
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| William Blair | Outperform | Oct 16, 2026 | |
| UBS | Buy | $11 | Oct 15, 2026 |
| Ladenburg Thalmann | Buy | $10 | Oct 1, 2026 |
| Truist Securities | Buy | $15 | Apr 29, 2026 |
| BofA Securities | Buy | $38 | Feb 5, 2026 |
| Wedbush | Outperform | $33 | Dec 12, 2025 |
| RBC Capital Markets | Outperform | $27 | Dec 9, 2025 |
Questions about Raymond James and WVE
- What is Raymond James's price target for WVE?
- Raymond James's latest stated price target for Wave Life Sciences Inc. (WVE) is $14, from its action on Jun 11, 2025.
- What is Raymond James's rating on WVE?
- Raymond James rates WVE Outperform, a bullish rating, as of Jun 11, 2025.
- When did Raymond James last change its view on WVE?
- On Jun 11, 2025, Raymond James resumes coverage at Outperform, price target $14.
- How does Raymond James's WVE target compare with other analysts?
- Across 6 firms with a WVE price target in the last 12 months, the median target is $21.
All Raymond James ratingsWVE news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.